OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Neurology is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Transmembrane protein interacts with α-synuclein to confer risk of PD	548
Lymphatic propagation of α-synuclein	346
Promising results for antisense RNA therapy in mouse models of diffuse midline glioma	346
Brain stimulation aids walking after spinal injury	310
ANA2025 marks important milestones for the ANA and NINDS	258
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications	256
Refining oxytocin therapy for autism: context is key	236
Reply to ‘Perils and pitfalls of near-death experience research’	233
Ventricular enlargement caused by aducanumab	228
Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms	226
Global synergistic actions to improve brain health for human development	220
Neural cell state shifts and fate loss in ageing and age-related diseases	213
Microglia, spreaders of Aβ seeds	209
NODDI reveals brain microstructural changes in multiple sclerosis	206
CD11c+ macrophages mediate brain-to-gut α-synuclein trafficking	205
Disease-specific modifications of tau protein	183
Continuous levodopa production by an artificial enzyme	166
Imperatives and co-benefits of research into climate change and neurological disease	156
TREM2 mediates phagocytosis in glioblastoma	150
Study reveals new ALS risk genes	143
SEQUINS — a new initiative to address disparities in neurology	138
Nir Giladi (1955–2024)	134
Rapidly progressive dementias — leukodystrophies as a potentially treatable cause	132
Spinal muscular atrophy treatment in utero	132
The impact of rare genetic variants on Alzheimer disease	126

Mitochondrial DNA instability in Huntington disease	116
The Digitized Memory Clinic	112
The role of the gut microbiota in multiple sclerosis	110
Psychosis-causing lesions mapped to a hippocampal circuit	108
Neuroinflammation predicts cognitive decline in FTD	106
Implications of AD plasma and PET biomarker discordance	105
Ultrasound lets gene therapy into the brain	105
Menopause influences tau pathology	103
Role for endogenous retrovirus in FTD	102
Brain volume is associated with cognition in MS	94
Amyloid plaques: hotspots for microglial turnover	91
Neurological care for LGBT+ people	91
MRI-based deep learning for TLE diagnosis	89
Challenges of combining multimodal data in assessment of people with traumatic brain injury	89
Diversity, equity and inclusion in neurology	87
Brain imaging illuminates cognitive impairment in multiple sclerosis	84
Gene therapy for seizures in focal cortical dysplasia	83
Management of freezing of gait — mechanism-based practical recommendations	80
Implementation of the 2024 revision of the McDonald criteria for multiple sclerosis	79
Author Correction: Viral pathogens increase risk of neurodegenerative disease	77
First trials test targeting of α-synuclein for Parkinson disease	75
Parkinson disease pathology can originate in the kidney	70
Precision neuroimmunology in multiple sclerosis — the horizon is near	70
APOE ε4 influences Parkinson disease progression	69
α-Synuclein pathology as a target in neurodegenerative diseases	68
The challenges of anti-tau therapeutics in Alzheimer disease	68
The noradrenergic subtype of Parkinson disease: from animal models to clinical practice	63
Blood GFAP as an emerging biomarker in brain and spinal cord disorders	62
Food is brain medicine — relevance and translation to neurology	61
Evidence for altered astrocyte function in Duchenne muscular dystrophy	60
Glymphatic dysfunction in PD clinical progression	60
Neurosteroids alleviate seizures in rats	60
A new biological classification for Parkinson disease	59
Addressing disparities in neurology by building the workforce in LMICs	58
Ultrasound ablation treatment for PD	57
Thalamic inflammation — a therapeutic target for brain injury?	56
Author Correction: Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus	55
Post-COVID dysautonomias: what we know and (mainly) what we don’t know	55
Spinal cord stimulation for the treatment of chronic pain	52
New IDEAS about amyloid, race and dementia disparities	52
Coeliac disease as a model for understanding multiple sclerosis	52
Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions	50
Knowing the enemy: strategic targeting of complement to treat Alzheimer disease	49
Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus	49
From the prodromal stage of multiple sclerosis to disease prevention	48
The global and regional burden of diabetic peripheral neuropathy	48
Synaptic degeneration in Alzheimer disease	46
The role of glial cells in multiple sclerosis disease progression	45
Exosomal microRNA is promising biomarker in PD	44
X-chromosome variants and PD in Latin America	44

Is Alzheimer disease a disease?	44
Oligomeric tau could spread through synapses in AD	44
Hypothyroidism is associated with dementia risk	43
Continuing evolution of migraine-specific therapies — targeting migraine with precision and persistence	43
Neurofilament light chain induces neuroinflammation	42
Genetic susceptibility determines Epstein–Barr-virus-associated risk of multiple sclerosis	42
Cognitive impairment and World Trade Centre-related exposures	41
Global epidemiology of migraine and its implications for public health and health policy	40
Neurology in 2025 — reflections from Africa	40
Peripheral nervous system immune-related adverse events due to checkpoint inhibition	40
Limbic-predominant age-related TDP43 encephalopathy (LATE) neuropathological change in neurodegenerative diseases	39
Risk locus for paediatric astrocytoma identified	39
The inter-relationship between delirium and dementia: the importance of delirium prevention	39
Dual function of biomolecular condensates	38
Moving towards meaningful patient and public engagement	38
α-Synuclein seeds in amyotrophic lateral sclerosis	38
T cells implicate Epstein–Barr virus in multiple sclerosis pathogenesis	37
Prognostic plasma biomarkers for spinal cord injury	36
Change in stroke outcomes over 20 years	36
Multi-ancestry GWAS identifies 16 novel Alzheimer disease risk loci	36
The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology	34
Facioscapulohumeral muscular dystrophy: the road to targeted therapies	34
Impaired glymphatic drainage links amyloid and tau to cognitive dysfunction	34
Safety and efficacy of COVID-19 vaccines in people with neurological disorders	33
The role of astrocytic α7 nicotinic acetylcholine receptors in Alzheimer disease	32
Insights from 25 years of onabotulinumtoxinA in migraine — mechanisms and management	31
Inflammasomes in neurological disorders — mechanisms and therapeutic potential	31
CAR T cells offer hope in glioblastoma	30
Reactive astrocyte biomarkers mirror Alzheimer disease pathology	29
Neurology in 2025 — reflections from the USA	27
New developments in guidelines for brain death/death by neurological criteria	26
Plasma extracellular vesicle biomarkers for frontotemporal dementia and related disorders	26
Origins and immunopathogenesis of autoimmune central nervous system disorders	26
Huntington disease-like 2: insight into neurodegeneration from an African disease	26
High rate of epilepsy in young individuals who died with COVID-19	25
Neurogenesis altered in multiple neurodegenerative diseases	25
Twin study probes non-heritable immune aspects of multiple sclerosis	24
Serum NfL as an MS biomarker	23
Does antiherpetic antiviral therapy reduce the risk of dementia?	23
John Q. Trojanowski	22
ALS pathogenesis linked to actin barrier collapse	21
Aberrant protein networks in Alzheimer disease	21
AI aces diagnosis of chronic ataxias	20
BCAS1+ oligodendrocytes aid remyelination in MS	20
Pharmacological rehabilitation for stroke	19
Addressing disparities in the global epidemiology of stroke	18
Alzheimer disease in African American individuals: increased incidence or not enough data?	18
Antisense oligonucleotide shows potential in Charcot–Marie–Tooth disease	18
Author Correction: The complex aetiology of cerebral palsy	18
The murky waters of sex differences in post-stroke cognitive impairment	17
Neuroprognostication: a conceptual framework	17
AI and protein structure and function in neurological disease: relevance to disease management	17
Pathogenetic mechanisms and treatment targets in cerebral malaria	16
Genome-wide analysis furthers decoding of Alzheimer disease genetics	16
Molecular biomarkers for vascular cognitive impairment and dementia	16
Charting brain development across the human lifespan	16
Effects of diet on MS onset and course	15
Clocking the age of Parkinson disease onset	15
Nusinersen treatment response markers	15
Altered muscle cholesterol transport in ALS	14
From adaptive deep brain stimulation to adaptive circuit targeting	13
Addressing racial inequities in neuropsychological assessment requires international prescriptive standards, not demographically adjusted norms	12
Mechanistic insights into the interaction between epilepsy and sleep	12
Nanoprobe for blood–brain barrier changes	12
Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis	12
Predictive tools in psychosis: what is ‘good enough’?	12
Advancing multiple sclerosis management in older adults	12
Alzheimer disease seen through the lens of sex and gender	12
Markers help to predict dementia with Lewy bodies	11
Shared glial pathology in HD and schizophrenia	11
Sex and gender in neurodevelopmental conditions	11
Multidimensional MRI detects astrogliosis	11